Intravenous Bolus of Dexmedetomidine for Treatment of Severe Shivering After Caesarean Delivery Under Combined Spinal-Epidural Anaesthesia: A Randomized Dose-Response Study
Meijuan Yang,ShuXi Li,Dan Drzymalski,Xinzhong Chen
DOI: https://doi.org/10.2147/dddt.s456289
IF: 4.3188
2024-06-20
Drug Design Development and Therapy
Abstract:Meijuan Yang, 1, &ast ShuXi Li, 1, &ast Dan Drzymalski, 2 Xinzhong Chen 1 1 Department of Anaesthesia, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China; 2 Department of Anaesthesiology and Perioperative Medicine, Tufts Medical Centre, Boston, MA, USA &astThese authors contributed equally to this work Correspondence: Xinzhong Chen, Tel +86-571-87061501, Fax +86-571-87061878, Email Purpose: Shivering occurs frequently after caesarean delivery. The present study aimed to investigate the ED50 and ED95 of an intravenous (i.v.) bolus of dexmedetomidine for treating severe shivering after caesarean delivery under combined spinal-epidural anaesthesia. Patients and methods: Seventy-five parturients with severe shivering after caesarean delivery were randomized into one of the five groups to receive an i.v. bolus of 0.2 (Group D1), 0.25 (Group D2), 0.3 (Group D3), 0.35 (Group D4) or 0.4 (Group D5) μg/kg of dexmedetomidine. Effectiveness of shivering treatment was defined as a standardized shivering score decreasing to ≤ 1 within 10 min of dexmedetomidine injection. The ED50 and ED95 were determined by probit regression. Adverse effects were also compared among the groups. Results: The ED50 and ED95 of i.v. dexmedetomidine to treat severe shivering were 0.23 (95% CI, 0.16– 0.26) μg/kg and 0.39 (95% CI, 0.34– 0.52) μg/kg, respectively. No difference in the incidence of adverse effects was found between groups. Conclusion: An i.v. bolus of 0.39 μg/kg of dexmedetomidine will treat 95% of parturients experiencing severe shivering after caesarean delivery. Keywords: dexmedetomidine, shivering, caesarean delivery Shivering, characterized by involuntary, repetitive activity of skeletal muscles, is one of the most common complications during and especially after caesarean delivery under neuraxial anaesthesia with an incidence of up to 50%–85%. 1–3 After caesarean delivery, shivering can cause maternal discomfort and anxiety, interfere with blood pressure and oxygen saturation monitoring as well as electrocardiograms. 4 Therefore, developing strategies for treating shivering may improve the care we provide for our parturients. Several medication classes, including opioids, 5-hydroxytryptamine3 (5-HT3) receptor antagonists, α2-receptor agonists and N-methyl-D-aspartate (NMDA)-receptor antagonists, have been used to prevent or treat perioperative shivering based on the possible mechanisms by which the central thermoregulatory mechanisms can be modified. 5–8 However, many anti-shivering agents are restricted by their side effects. For example, meperidine and tramadol may induce nausea and vomiting, which is very distressing for the patient, and ketamine can lead to hypertension and tachycardia. 9–11 Dexmedetomidine, a highly specific and selective α2 adrenoreceptor agonist, is considered a valuable medication in the current obstetric anaesthesia practice with a favorable risk–benefit ratio. 12,13 Previous studies have demonstrated that i.v. dexmedetomidine could effectively reduce the incidence and intensity of shivering after caesarean delivery under neuraxial anaesthesia. 14–16 However, the dose-response of i.v. dexmedetomidine for treating shivering in parturients during Caesarean delivery has not been studied. We conducted a prospective, randomized, double-blinded clinical trial to determine the dose–response characteristics of an i.v. bolus of dexmedetomidine for treating severe shivering after Caesarean delivery in parturients undergoing combined spinal–epidural anaesthesia and to derive values for the bolus dose of dexmedetomidine that would be effective for treating severe shivering in 50% (ED50) and 95% (ED95) of parturients. The study protocol was approved by the Ethical Review Board of Women's Hospital, School of Medicine, Zhejiang University (approval number IRB-20200254-R) and registered on the Chinese Clinical Trial Registry ( http://www.chictr.org.cn ) (registration no: ChiCTR2000039264, PI: Meijuan Yang, registered on 22nd October 2020). Written informed consent was obtained from all participants. This study adheres to the applicable CONSORT guidelines for randomized trials. Parturients with a singleton pregnancy, American Society of Anaesthesiologists physical status (ASA II), ages between 20 and 45 years, and a gestational age ≥37 weeks scheduled for elective Caesarean delivery were enrolled in the study. Exclusion criteria were as follows: gestational hypertension, diabetes mellitus, obesity (body mass index >35 kg/m 2 ), height 170 cm, an initial body temperature >38°C or <36°C, c -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal